Pure Global AI
NCT06144788Not yet recruiting

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients With Type 2 Diabetes Mellitus
Jeil Pharmaceutical Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
SGLT2 inhibitor
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jeil Pharmaceutical Co., Ltd.
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 2
Start date
Nov 01, 2023
End date
Apr 01, 2025
Enrollment
156 participants
Primary outcome

Changes in HbA1c at the 12 week from the baseline

Summary

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic
 Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients with
 Type 2 Diabetes Mellitus

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06144788
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06144788 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jeil Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 156 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.